Device type · NAJ
Agents, Embolic, For Treatment Of Uterine Fibroids
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
NAJ
Obstetrics & Gynecology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
9
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Agents, Embolic, For Treatment Of Uterine Fibroids
- Product code
- NAJ
- Device class
- Class II
- Review panel
- Obstetrics & Gynecology
- Regulation
- 21 CFR 870.3300
- FDA record
- Classification database entry for NAJ
Latest FDA decisions
- Bearing nsPVA Express510(k)
K233813 · Decided Dec 21, 2023 · 21 days after receipt
Device type: Agents, Embolic, For Treatment Of Uterine Fibroids (NAJ) · Cardiology
Suzhou Hengrui Callisyn Biomedical Co., Ltd.
K173871 · Decided Sep 17, 2018 · 271 days after receipt
Device type: Agents, Embolic, For Treatment Of Uterine Fibroids (NAJ) · Cardiology
Reports received
9
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
6
67% of reports
Injury reports
3
33% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 1 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 1 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 1 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 1 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 4 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 2 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 2 | 0 | 0 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Adverse Event Without Identified Device or Use Problem3
- Break2
- Leak/Splash2
4 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions6
- Muscle Weakness/Atrophy2
- Abscess1
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2109-2009 · Started Aug 17, 2009 · Posted by FDA Sep 15, 2009
Reason given: Compromised sterility: Boston Scientific is initiating a Recall Removal for twenty (20) UPN codes and 638 associated lots/batches of its Contour SE Microspheres product. All affected product is packaged within a vial. Boston Scientific has determined that, for affected products, the sterile barrier in the packaging...
Cause as FDA categorized it: Process design
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.